Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Leukemia that does not responded to treatment is called refractory chronic lymphocytic leukemia. Symptoms include fever and infection, abnormal bleeding, shortness of breath, weight loss and swelling of lymph nodes. Treatment includes stem cell transplantation or bone marrow transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 21, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Refractory Chronic Lymphocytic Leukemia (CLL).

Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Refractory Chronic Lymphocytic Leukemia (CLL) Overview
Therapeutics Development
Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview
Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies
Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes
Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
4SC AG
AbbVie Inc
Arno Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Cellular Biomedicine Group, Inc.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Incyte Corporation
Innate Pharma S.A.
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
LFB S.A.
Lymphocyte Activation Technologies, S.A.
Medicenna Therapeutics, Inc.
Millennium Pharmaceuticals Inc
MorphoSys AG
Novartis AG
Oncternal Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
Portola Pharmaceuticals, Inc.
Sanofi
Tragara Pharmaceuticals, Inc.
Verastem, Inc.
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dezapelisib + itacitinib adipate) - Drug Profile
4SC-202 - Drug Profile
acalabrutinib - Drug Profile
ACP-319 - Drug Profile
afuresertib hydrochloride - Drug Profile
AGS-67E - Drug Profile
AR-42 - Drug Profile
AT-7519 - Drug Profile
atezolizumab - Drug Profile
BI-836826 - Drug Profile
BMS-986016 - Drug Profile
buparlisib hydrochloride - Drug Profile
CBM-C19.1 - Drug Profile
CBM-C20.1 - Drug Profile
CC-122 - Drug Profile
Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile
Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile
cerdulatinib - Drug Profile
duvelisib - Drug Profile
HMPL-523 - Drug Profile
idelalisib - Drug Profile
IMGN-529 - Drug Profile
IMMU-114 - Drug Profile
JCAR-014 - Drug Profile
JCAR-015 - Drug Profile
lirilumab - Drug Profile
MDNA-56 - Drug Profile
monalizumab - Drug Profile
MOR-208 - Drug Profile
nivolumab - Drug Profile
obinutuzumab - Drug Profile
PCAR-019 - Drug Profile
PCAR-119 - Drug Profile
pilaralisib - Drug Profile
S-055746 - Drug Profile
selinexor - Drug Profile
spebrutinib besylate - Drug Profile
TAK-659 - Drug Profile
TG-02 - Drug Profile
tisagenlecleucel-T - Drug Profile
ublituximab - Drug Profile
UC-961 - Drug Profile
ulocuplumab - Drug Profile
urelumab - Drug Profile
venetoclax - Drug Profile
Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2016
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2016
Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2016
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook